Progesterone negatively regulates BCRP in progesterone receptor-positive human breast cancer cells

Cellular Physiology and Biochemistry

Volumn 32, Issue 2, 2013, Pages 344-354

  Wu, Xiaojuan ^a   Zhang, Xiaofang ^a   Sun, Limin ^b   Zhang, Hui ^a   Li, Li ^a   Wang, Xiao ^a   Li, Weiwei ^a   Su, Peng ^a   Hu, Jing ^a   Gao, Peng ^a   Zhou, Gengyin ^a  

^a SHANDONG UNIVERSITY   (China)

^b Shandong Jiaotong Hospital   (China)

Author keywords

Breast cancer cells; Breast cancer resistance protein; Progesterone; RU 486; Transcriptional regulation

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; MESSENGER RNA; MIFEPRISTONE; MITOXANTRONE; PROGESTERONE; PROGESTERONE RECEPTOR;

ARTICLE; BREAST CELL; CANCER CELL; CELL SURVIVAL; CHEMOSENSITIZATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; BCRP GENE; BREAST CANCER; CHEMOSENSITIVITY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CYTOMETRY; DOWN REGULATION; FEMALE; GENE; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; WESTERN BLOTTING;

ATP-BINDING CASSETTE TRANSPORTERS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM PROTEINS; PROGESTERONE; PROMOTER REGIONS, GENETIC; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, PROGESTERONE; RNA, MESSENGER;

EID: 84885645245     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000354442     Document Type: Article

References (43)

1. Dean M, Hamon Y, Chimini G: The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001;42:1007-1017. (Pubitemid 32645780)
2. Kawabata S, Oka M, Soda H, Shiozawa K, Nakatomi K, Tsurutani J, Nakamura Y, Doi S, Kitazaki T, Sugahara K, Yamada Y, Kamihira S, Kohno S: Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin Cancer Res 2003;9:3052-3057. (Pubitemid 36993267)
3. Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ: Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res 2005;65:6640-6650. (Pubitemid 41060700)
4. Carcaboso AM, Elmeliegy MA, Shen J, Juel SJ, Zhang ZM, Calabrese C, Tracey L, Waters CM, Stewart CF: Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas. Cancer Res 2010;70:4499-4508.
5. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sei USA 1998;95:15665-15670. (Pubitemid 29018757)
6. Staud F, Pavek P: Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol 2005;37:720-725. (Pubitemid 40202994)
7. Volk EL, Farley KM, Wu Y, Li F, Robey RW, Schneider E: Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 2002;62:5035-5040. (Pubitemid 34984431)
8. Yang CH, Schneider E, Kuo ML, Volk EL, Rocchi E, Chen YC: BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells. Biochem Pharmacol 2000;60:831-837. (Pubitemid 30621668)
9. Lage H, Dietel M: Effect of the breast-cancer resistance protein on atypical multidrug resistance. Lancet Oncol 2000;1:169-175.
10. Kiani J, Khan A, Khawar H, Shuaib F, Pervez S: Estrogen receptor alpha-negative and progesterone receptor-positive breast cancer: lab error or real entity? Pathol Oncol Res 2006;12:223-227.
11. Zhang Y, Zhou G, Wang H, Zhang X, Wei F, Cai Y, Yin D: Transcriptional upregulation of breast cancer resistance protein by 17beta-estradiol in ERalpha-positive MCF-7 breast cancer cells. Oncology 2006;71:446-455.
12. Wang H, Lee EW, Zhou L, Leung PC, Ross DD, Unadkat JD, Mao Q: Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells. Mol Pharmacol 2008;73:845-854. (Pubitemid 351397889)
13. Zheng ZY, Bay BH, Aw SE, Lin VC: A novel antiestrogenic mechanism in progesterone receptor-transfected breast cancer cells. J Biol Chem 2005;280:17480-17487. (Pubitemid 41389220)
14. Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD: Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database Syst Rev 2006:CD006019.
15. Tanmahasamut P, Wongwananuruk T: Challenging Regimen for Long-Term Conservative Treatment of Endometrial Adenocarcinoma in Young Women: A Case Report and Review of the Literature. Case Rep Oncol 2010;3:380-385.
16. Rugo HS: The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol 2008;19:16-27.
17. Li WT, Zhou GY, Song XR, Chi WL, Ren RM, Wang XW: Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference. Neoplasma 2005;52:219-224. (Pubitemid 40776433)
18. Wijesuriya HC, Bullock JY, Faull RL, Hladky SB, Barrand MA: ABC efflux transporters in brain vasculature of Alzheimers subjects. Brain Res 2010;1358:228-238.
19. Sun Y, Zhang T, Gao P, Meng B, Gao Y, Wang X, Zhang J, Wang H, Wu X, Zheng W, Zhou G: Targeting glucosylceramide synthase downregulates expression of the multidrug resistance gene MDR1 and sensitizes breast carcinoma cells to anticancer drugs. Breast Cancer Res Treat 2010;121:591-599.
20. Sieuwerts AM, Klijn JG, Peters HA, Foekens JA: The MTT tetrazolium salt assay scrutinized: how to use this assay reliably to measure metabolic activity of cell cultures in vitro for the assessment of growth characteristics, IC50-values and cell survival. Eur J Clin Chem Clin Biochem 1995;33:813-823.
21. Garcia-Escarp M, Martinez-Munoz V, Sales-Pardo I, Barquinero J, Domingo JC, Marin P, Petriz J: Flow cytometry-based approach to ABCG2 function suggests that the transporter differentially handles the influx and efflux of drugs. Cytometry A 2004;62:129-138. (Pubitemid 39579243)
22. Doyle LA, Ross DD: Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 2003;22:7340-7358. (Pubitemid 37487163)
23. Sarkadi B, Ozvegy-Laczka C, Nemet K, Varadi A: ABCG2-a transporter for all seasons. FEBS Lett 2004;567:116-120.
24. Scheffer GL, Maliepaard M, Pijnenborg AC, van Gastelen MA, de Jong MC, Schroeijers AB, van der Kolk DM, Allen JD, Ross DD, van der Valk P, Dalton WS, Schellens JH, Scheper RJ: Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone-and topotecan-resistant cell lines. Cancer Res 2000;60:2589-2593. (Pubitemid 30318229)
25. Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ, Schellens JH: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001;61:3458-3464. (Pubitemid 32695041)
26. Mao Q, Unadkat JD: Role of the breast cancer resistance protein (ABCG2) in drug transport. Aaps J 2005;7:E118-133.
27. Yoshikawa M, Ito A, Ishikawa T, Ikegami Y: [Drug resistance mediated by ABC transporters]. Gan To Kagaku Ryoho 2004;31:1-6.
28. Imai Y, Tsukahara S, Ishikawa E, Tsuruo T, Sugimoto Y: Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance. Jpn J Cancer Res 2002;93:231-235. (Pubitemid 34464356)
29. Sugimoto Y, Tsukahara S, Imai Y, Sugimoto Y, Ueda K, Tsuruo T: Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists. Mol Cancer Ther 2003;2:105-112.
30. Imai Y, Ishikawa E, Asada S, Sugimoto Y: Estrogen-mediated post transcriptional down-regulation of breast cancer resistance protein/ABCG2. Cancer Res 2005;65:596-604.
31. Zhang Y, Wang H, Wei L, Li G, Yu J, Gao Y, Gao P, Zhang X, Wei F, Yin D, Zhou G: Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells. Breast Cancer Res Treat 2010;123:679-689.
32. Osborne CK: Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998;51:227-238. (Pubitemid 29054556)
33. Nikolic-Vukosavljevic D, Kanjer K, Neskovic-Konstantinovic Z, Vukotic D: Natural history of estrogen receptor-negative, progesterone receptor-positive breast cancer. Int J Biol Markers 2002;17:196-200. (Pubitemid 35370063)
34. Keshgegian AA, Cnaan A: Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome. Arch Pathol Lab Med 1996;120:970-973. (Pubitemid 26346462)
35. Ee PL, He X, Ross DD, Beck WT: Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference. Mol Cancer Ther 2004;3:1577-1583. (Pubitemid 40136713)
36. Graham JD, Mote PA, Salagame U, van Dijk JH, Balleine RL, Huschtscha LI, Reddel RR, Clarke CL: DNA replication licensing and progenitor numbers are increased by progesterone in normal human breast. Endocrinology 2009;150:3318-3326.
37. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ: Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999;84:4559-4565.
38. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R: Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. Jama 2000;283:485-491. (Pubitemid 30062864)
39. Li J, Xu LZ, He KL, Guo WJ, Zheng YH, Xia P, Chen Y: Reversal effects of nomegestrol acetate on multidrug resistance in adriamycin-resistant MCF7 breast cancer cell line. Breast Cancer Res 2001;3:253-263. (Pubitemid 32633348)
40. Wu X, Zhang X, Zhang H, Su P, Li W, Li L, Wang Y, Liu W, Gao P, Zhou G: Progesterone receptor downregulates breast cancer resistance protein expression via binding to the progesterone response element in breast cancer. Cancer Sei 2012;103:959-967.
41. Baglietto L, Severi G, English DR, Krishnan K, Hopper JL, McLean C, Morris HA, Tilley WD, Giles GG: Circulating steroid hormone levels and risk of breast cancer for postmenopausal women. Cancer Epidemiol Biomarkers Prev 2010;19:492-502.
42. Zhu Y, Hanna RN, Schaaf MJ, Spaink HP, Thomas P: Candidates for membrane progestin receptors-past approaches and future challenges. Comp Biochem Physiol C Toxicol Pharmacol 2008;148:381-389.
43. Wang H, Zhou L, Gupta A, Vethanayagam RR, Zhang Y, Unadkat JD, Mao Q: Regulation of BCRP/ABCG2 expression by progesterone and 17beta-estradiol in human placental BeWo cells. Am J Physiol Endocrinol Metab 2006;290:E798-807.